Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. - Wikidata - awgldk - TriplyDB

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

http://www.wikidata.org/entity/Q43162616

about

Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas Children's Oncology Group's 2013 blueprint for research: renal tumors Targeted therapeutic strategies for the management of renal cell carcinoma The metabolic basis of kidney cancer Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.PD-L1 expression in nonclear-cell renal cell carcinoma.The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.TFE3 Translocation-Associated Renal Cell Carcinoma Presenting as Avascular Necrosis of the Femur in a 19-Year-Old Patient: Case Report and Review of the Literature.Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling Recent developments in the treatment of renal cell carcinoma.Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusion: A Rare Case Report with Review of the Literature.Renal cell carcinoma in children and adolescents.Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features.Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report A Review of Translocation T(6;11) Renal Cell Carcinoma Tumors in the Adult Patient.A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy Cardiopulmonary bypass-assisted surgery for the treatment of Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a tumor thrombus within the inferior vena cava: A case report Xp 11.2 translocation renal carcinoma in young adults; recently classified distinct subtype.Radiologic-pathologic correlation of renal cell carcinoma associated with Xp11.2 translocation.A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.Cutaneous metastases during an aggressive course of Xp11.2 translocation renal cell carcinoma in a teenager.

P2860

Q26752945-642DB523-2963-47FC-9775-FFE7119EDA2A Q27000449-C627BF5D-2EA8-4DFC-BC51-610AE69E383E Q27013846-49D88BC4-2B67-4F0B-96AD-2279FE7DF618 Q27023273-4C48B64D-39A4-4B74-8ADB-89D0A49BDC9B Q31046172-CDF323EE-52E4-4489-BD1A-71346F4C4A3A Q33401272-4461019B-C9A7-4E66-84E3-710D6065B14A Q33761537-90326976-857A-4A93-AD7C-5D50C2ABA3CF Q34194075-25177632-A74C-4E44-A853-2636C82ED1A8 Q34206517-80A7D7B8-7DB3-425F-9A7A-95A416687BAB Q34206531-3B728146-E7B5-4639-B42E-DA4074F47AE0 Q34882798-BC1C6682-CA81-4CAF-944D-813239C5C8AA Q35133904-A2408FEB-5F64-4763-B37A-8A5B640E8A90 Q35293660-65D6A5B2-567C-477F-87DA-345B17BDA64E Q35315403-539DC066-0CD9-4537-8E97-4E97ECC9C0E8 Q35632133-5EB39B1A-3292-48BF-9CCA-45B6FC2CE8D9 Q36001179-649E0B4F-6632-4043-B37C-9150A942EBEB Q36105584-84975E16-781B-4E73-A926-14FA896D08DA Q36151526-C3D2B5CA-A89E-4AE7-8B60-4297D81C655C Q36182819-A308A0AD-F597-4FCB-B201-4AE7DE3CDF9C Q36205571-9992B6AE-2017-4785-A07D-56360941F2EF Q36341169-92201071-4B6A-4B2C-8C3B-532604F40556 Q37284328-1F46AB38-EA7B-4D3D-B935-D40CBE362C64 Q37300942-B73ACB7D-1858-4B07-95C8-54B56A60132C Q37435939-49B2FED0-463E-416E-A290-4AADC3F9D05D Q37812610-EDF3A914-8ABF-4ED6-BBEA-480749C2569B Q37836508-A753B85B-9837-425F-866C-D42DEE03ADB7 Q38067125-D2E00547-ACEB-4406-A793-BD3B5C73D52E Q38168996-DD9E45FB-2B5B-4CCA-BE7F-F8749C2EECBF Q38388597-CD470968-6C58-4CA5-A5B5-F777F4162516 Q38740145-4FA178E6-79AA-4EF0-A45A-82C19A82E14E Q39204706-877339B2-8401-4242-BA63-E5C7528F4B27 Q39298566-EF4E78B9-B31C-4B40-9CCE-A2641E7E5785 Q41126079-D7C008E5-04D9-4E2E-A0DD-B5A6654B7451 Q41971524-0ADDA51A-35F6-411C-9583-577C66C8D251 Q42215445-0BBC7DF6-1172-465C-B959-4A12754AB5C9 Q42717006-48F7DF82-9AF1-41DE-A3B5-09D892BF07D4 Q45867795-54339A4F-21AE-47D3-A19B-848D63468315 Q46979728-308A6F1A-A9A1-4B61-B8E0-0AED4E0FAEC9 Q47664030-954ED57D-1441-435A-879C-5F6EA8AF444C Q51157042-E93A175C-28E1-4C81-83DD-A2EC705E027F

P2860

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

http://www.wikidata.org/entity/Q43162616

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Targeted agents in metastatic ...... from the Juvenile RCC Network.

@en

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma

@nl

type

label

Targeted agents in metastatic ...... from the Juvenile RCC Network.

@en

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma

@nl

prefLabel

Targeted agents in metastatic ...... from the Juvenile RCC Network.

@en

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma

@nl

P1433

Q43162616-33F16608-B657-4A8D-B226-6AF382166006

P1476

Q43162616-E59842D9-5E75-4F7F-A1EB-B0D30FF6976C

P2093

Q43162616-104684F5-DE3E-4E02-A4BE-6A9436506E95

Q43162616-184764D5-2E0B-4CE3-863F-F76F06B99574

Q43162616-3A4C8A0E-051F-4744-A3A7-30DA93BBF30A

Q43162616-4CC89D6F-9F26-4AD9-BFF7-291D41BF973B

Q43162616-59E6C48F-A2BE-48D3-84A9-BF8959BA4EDE

Q43162616-93A4BF03-5422-4B22-8CBC-203903BF35AC

Q43162616-984018B2-5245-4C13-B344-904077957995

Q43162616-A19E0CF8-4717-4988-90E6-08B46E2FFA6B

Q43162616-A9269478-5FBE-4378-8938-C95A90340C85

Q43162616-AF8320C4-99BC-4A2C-98D6-FF55A8F99D11

P2860

Q43162616-0F782C3E-EB09-4955-9277-57FF8209B701

Q43162616-23D3452F-E520-429E-9DD3-C4013065D257

Q43162616-261CD5AD-70D4-4019-8813-69E19E113D60

Q43162616-603C8509-C31A-4E1B-B210-6BBB4E25CD29

Q43162616-69130E93-5F17-4341-A26C-11C927D62C3F

Q43162616-79F70067-A13C-4B53-BB70-73395096AF50

Q43162616-82C5A62E-71CB-4BED-9329-BAFB68C296CB

Q43162616-8C0DD349-2450-4775-9134-9DD42CF7906E

Q43162616-8DE91564-5EEF-40AF-BE70-48C05BE54A72

Q43162616-A53C348A-22C7-44CC-AD87-E14D36A57CC9

P304

Q43162616-1361332F-F745-4200-8CE6-6B9565187601

P31

Q43162616-D04C07E3-A255-4539-AAAB-3E5ED42208BF

P356

Q43162616-EF983967-EBD4-48F1-BA15-36D7C0A5890C

P433

Q43162616-8DB6CF6C-A155-48FF-81A7-B1F4D6EB8E7E

P478

Q43162616-F80F23F3-8C6A-4480-BCC5-4CA0AA10A8D9

P577

Q43162616-23682CCE-C73A-4BFB-857D-E4B399564C9C

P698

Q43162616-959209D7-0588-47A6-9953-0CCEE84C3769

P356

P1433

Annals of Oncology

P1476

Targeted agents in metastatic ...... from the Juvenile RCC Network.

@en

P2093

A Guillot

http://www.w3.org/2001/XMLSchema#string

A Rustine

http://www.w3.org/2001/XMLSchema#string

B Billemont

http://www.w3.org/2001/XMLSchema#string

B Escudier

http://www.w3.org/2001/XMLSchema#string

C Theodore

http://www.w3.org/2001/XMLSchema#string

E Bompas

http://www.w3.org/2001/XMLSchema#string

G G Malouf

http://www.w3.org/2001/XMLSchema#string

G Schleiermacher

http://www.w3.org/2001/XMLSchema#string

J Couturier

http://www.w3.org/2001/XMLSchema#string

J Dutcher

http://www.w3.org/2001/XMLSchema#string

P2860

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Renal carcinoma-associated transcription factors TFE3 and TFEB are leukemia inhibitory factor-responsive transcription activators of E-cadherin

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Response to sunitinib malate in advanced alveolar soft part sarcoma.

RECIST revisited: a review of validation studies on tumour assessment.

Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum.

An aggressive course of Xp11 translocation renal cell carcinoma in a 28-year-old man.

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

P304

1834-1838

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ029

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20154303

http://www.w3.org/2001/XMLSchema#string